Form 4: OmniAb Director Steven Crouse Granted 20,000 RSUs and 40,000 Stock Options

OmniAb, Inc. Director Steven C. Crouse was granted 20,000 Restricted Stock Units and 40,000 stock options on June 17, 2025, as disclosed in a recent SEC Form 4 filing.

Summary

• Steven C. Crouse, a Director of OmniAb, Inc. (OABI), received equity awards on June 17, 2025, as reported in a Form 4 filing.
• The awards include a grant of 20,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of the Issuer's Common Stock.
• These RSUs were granted at a price of $0, and following this transaction, Mr. Crouse beneficially owns 60,000 RSUs.
• Additionally, Mr. Crouse was granted 40,000 stock options with an exercise price of $1.7 per share.
• These stock options were also granted at a price of $0, resulting in Mr. Crouse beneficially owning 40,000 stock options after the transaction.
• Both the RSUs and stock options are set to vest in full on the earlier of the date of the next annual meeting of the Company's stockholders following the grant date or the first anniversary of the grant date.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive sign of alignment between management and shareholders, but does not contain information that would significantly alter the company's fundamental outlook or financial performance.

Positives

• Director Steven C. Crouse received a grant of 20,000 Restricted Stock Units (RSUs), which aligns his interests with those of the company's shareholders.
• Mr. Crouse was also granted 40,000 stock options, providing further incentive for his long-term commitment and contribution to the company's performance.
• The equity grants increase the director's beneficial ownership in OmniAb, demonstrating continued confidence and alignment with the company's future success.

Future Outlook

The Restricted Stock Units and Stock Options granted to Director Steven C. Crouse are scheduled to vest in full on the earlier of the date of the next annual meeting of the Company's stockholders following the grant date or the first anniversary of the grant date, aligning future compensation with company performance.

Industry Context

This Form 4 filing reflects a standard equity compensation practice for directors in the biotechnology or pharmaceutical industry, aiming to align executive and director incentives with long-term shareholder value creation. Such grants are common mechanisms to retain key talent and encourage commitment to the company's strategic goals.

Related Party Transactions

• The equity grants to Director Steven C. Crouse constitute a related party transaction, as they involve compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders by tying compensation to future stock performance.
• Employees: No direct impact on employees mentioned.
• Customers: No direct impact on customers mentioned.
• Suppliers: No direct impact on suppliers mentioned.
• Creditors: No direct impact on creditors mentioned.

Next Steps

• The Restricted Stock Units (RSUs) are expected to vest on the earlier of the next annual meeting of stockholders following the grant date or the first anniversary of the grant date.
• The Stock Options are expected to vest and become exercisable on the earlier of the next annual meeting of stockholders following the grant date or the first anniversary of the grant date.

Key Dates

Recommendation

Keywords

OmniAb, OABI, Steven C. Crouse, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership